Youcare Pharmaceutical Group Co., Ltd. clinical trials

Part of Fuyang Jingyue Yongshun Information Consulting Co., Ltd..

The registry lists 6 studies whose lead sponsor is Youcare Pharmaceutical Group Co., Ltd. or one of 1 company grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 12, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

6studies on the registry
6open to participants now
2reach primary completion within a year

Get an email when these change. Save the Youcare Pharmaceutical Group Co., Ltd. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Pipeline: 6 programmes

Each counted once: 6 with a study Youcare Pharmaceutical Group Co., Ltd. leads registered in the last two years.

Phase 1
Phase 2

5 from the earlier phases, besides the phase-3 view.

Sort

Programme	Main condition
YKYY013Phase 2 · 1 live · Hepatitis B · readout Mar 2027	Hepatitis B	Phase 2	1 / 1	Oct 2026	Mar 2027 est.
Phase 2 since 21 Oct 2026: Youcare Pharmaceutical Group Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. Next readout: 20 Mar 2027, the registry's estimate — the primary completion of NCT07933627study page ClinicalTrials.gov ↗ Read from the registry as written: no join or match was needed.
YKYY018Phase 2 · 1 live · readout Dec 2027	—	Phase 2	1 / 1	Sep 2026	Dec 2027 est.
Phase 2 since 2 Sept 2026: Youcare Pharmaceutical Group Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. Next readout: 10 Dec 2027, the registry's estimate — the primary completion of NCT07808268study page ClinicalTrials.gov ↗ Read from the registry as written: no join or match was needed.
YKYY032 groupYKYY032Phase 2 · 1 live · Hyperlipoproteinemias · readout Dec 2028	Hyperlipoproteinemias	Phase 2	1 / 1	Oct 2026	Dec 2028 est.
Phase 2 since 19 Oct 2026: Youcare Pharmaceutical Group Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. Next readout: 30 Dec 2028, the registry's estimate — the primary completion of NCT07914660study page ClinicalTrials.gov ↗ Read from the registry as written: no join or match was needed.
YKYY025Phase 1 · 1 live · readout Jul 2028	—	Phase 1	1 / 1	Jul 2026	Jul 2028 est.
Phase 1 since 2 Jul 2026: Youcare Pharmaceutical Group Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. Next readout: 1 Jul 2028, the registry's estimate — the primary completion of NCT07694557study page ClinicalTrials.gov ↗ Read from the registry as written: no join or match was needed.
YKYY031Phase 1 · 1 live · Neoplasms · readout Dec 2027	Neoplasms	Phase 1	1 / 1	May 2026	Dec 2027 est.
Phase 1 since 27 May 2026: Youcare Pharmaceutical Group Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. Next readout: 8 Dec 2027, the registry's estimate — the primary completion of NCT07631793study page ClinicalTrials.gov ↗ Read from the registry as written: no join or match was needed.

1 more — sign in to see them all, free: with every programme, filter by condition or phase and sort by first study or next readout.

“Registry” is the highest phase of Youcare Pharmaceutical Group Co., Ltd.’s own registered studies; Youcare Pharmaceutical Group Co., Ltd.’s own pipeline document is not read yet. “Next readout” is the earliest primary completion date still ahead among its live studies, as the registry states it (most are estimates). Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Coming up

2 of Youcare Pharmaceutical Group Co., Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

NNov ’26’26
DDec
JJan ’27’27
FFeb
1MMar
AApr
MMay
JJun
JJul
AAug
SSep
OOct
1NNov

All 2

Add all 2 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered2

Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide AnaloguesNov 12, 2026NCT07933627
Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)Nov 3, 2026NCT07914660

All 6 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

Open now6100%Not yet recruiting 3 · Recruiting 3

Phase

Phase 13
Phase 23

Where

China6

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Youcare Pharmaceutical Group Co., Ltd..

Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Subsidiary
Something wrong?
What is wrong with this name?Not part of Youcare Pharmaceutical Group Co., Ltd.Wrong relationship to Youcare Pharmaceutical Group Co., Ltd.Something else
What is right?A source, if you have one
No account needed. Please leave out personal details.
6 studies →

Studies

Recruiting first, then most recently updated. Showing 6 of 6.

Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide AnaloguesNot yet recruitingNCT07933627Phase 2
Sponsor listed in the registry: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)Not yet recruitingNCT07914660Phase 2
Sponsor listed in the registry: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid TumorsRecruitingNCT07631793Phase 1
Sponsor listed in the registry: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 InjectionRecruitingNCT07694557Phase 1
Sponsor listed in the registry: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
A Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY018 for Inhalation SolutionNot yet recruitingNCT07808268Phase 2
Sponsor listed in the registry: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 InjectionRecruitingNCT07786779Phase 1
Sponsor listed in the registry: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.